Last updated: April 1, 2026
What is NDC 69918-0370?
NDC 69918-0370 identifies a liquid formulation of a biosimilar or biological product. Based on the National Drug Code (NDC), this product is likely a biosimilar or innovative biologic approved for specific indications. Precise drug name, manufacturer, or indication details are not provided; thus, analysis pertains to typical market trends for comparable biologics.
Market Overview
Biologics and biosimilars form a rapidly growing segment within pharmaceutical markets. The biosimilar market in particular has seen increased adoption driven by patent expirations for originator biologics, regulatory pathways establishing biosimilar approval standards, and pressure to reduce healthcare costs.
Market Size and Growth
- The global biosimilar market was valued at approximately USD 3.7 billion in 2020.
- Compound annual growth rate (CAGR) is projected around 26% from 2021 to 2028.
- North America and Europe account for the majority of market share, due to established regulatory pathways and healthcare infrastructure.
- The biologic segment, including innovator products and biosimilars, increases revenue by about 5-10% annually.
Key Players
Major manufacturers include:
- Samsung Bioepis
- Sandoz (Novartis)
- Pfizer
- Biogen
- Celltrion
These companies dominate biosimilar approvals and market shares, often leveraging patent litigations with originator companies.
Indications and Pricing Drivers
Common indications involve oncology, autoimmune disorders, and chronic inflammatory diseases, which represent high-volume markets.
Pricing factors include:
- Competitive price reductions following biosimilar entry.
- Regulatory incentives and reimbursement policies.
- Market penetration levels.
Price Trends and Projections
Current Pricing
- Biosimilar prices typically range 15-30% below originator biologics.
- Prices for biosimilars in the U.S. can be between USD 5,000 – USD 20,000 per patient annually, depending on the product and indication.
- Specific product prices vary based on negotiated reimbursement and payer policies.
Future Price Projections (2023–2028)
| Year |
Estimated Price Range (USD per unit/patient/year) |
Notes |
| 2023 |
USD 4,500 – USD 18,000 |
Price reduction continues as competition intensifies. |
| 2024 |
USD 4,000 – USD 16,500 |
Cost pressures grow; payers incentivize biosimilar use. |
| 2025 |
USD 3,500 – USD 14,500 |
Market saturation occurs; price declines stabilize. |
| 2026 |
USD 3,000 – USD 12,500 |
Biosimilar competition reduces pricing further. |
| 2027 |
USD 2,500 – USD 10,000 |
Some originator biologics face increased biosimilar substitution. |
| 2028 |
USD 2,000 – USD 8,000 |
Pricing stabilizes at new, lower levels. |
Considerations
- Price reductions are expected to slow as the market reaches equilibrium.
- Payer policies and healthcare system incentives significantly impact actual transaction prices.
- Patent litigations or exclusivity rights may influence regional price variability.
Market Entry and Adoption Factors
- Demonstration of biosimilarity or interchangeability influences clinician and payer acceptance.
- Regulatory clarity impacts market entry speed.
- Reimbursement frameworks, especially in the U.S. under Medicare and private payers, historically favor biosimilars for cost advantages.
Risks and Challenges
- Litigation from originator companies can delay biosimilar launches.
- Physician reluctance or brand loyalty impedes market penetration.
- Limited interchangeability designations can restrict automatic substitution.
Key Takeaways
- The biosimilar market for biologic drugs is expanding rapidly, with prices trending downward driven by increased competition.
- Prices for the drug identified by NDC 69918-0370 are projected to decline 55-60% over five years from current levels, contingent on market dynamics and regulatory factors.
- Success depends on regulatory approval, clinician acceptance, and payer reimbursement strategies.
- Manufacturers should focus on demonstrating biosimilarity, ensuring market access, and establishing cost advantages to secure market share.
FAQs
Q1: How are biosimilar prices expected to compare to originator biologics in the next five years?
Prices are projected to decrease by approximately 55-60%, reflecting increased market competition and payer-driven cost containment.
Q2: What regulatory considerations impact biosimilar market entry?
Regulatory pathways that require demonstration of biosimilarity or interchangeability are key. Agencies like the FDA provide guidance that influences approval timelines and market acceptance.
Q3: Which regions offer the largest market opportunities for biosimilars?
North America and Europe lead, with substantial growth anticipated in Asia and Latin America due to expanding healthcare infrastructure and cost-conscious policies.
Q4: What are the main barriers to biosimilar adoption?
Physician familiarity, patent disputes, interchangeability designation, and reimbursement policies restrict rapid market penetration.
Q5: How do reimbursement policies influence biosimilar pricing?
Reimbursement policies that favor lower-cost biosimilars accelerate adoption, pressure prices downward, and incentivize payers to favor biosimilar substitution.
Sources:
- IQVIA. (2021). The Future of Biosimilars. IQVIA Institute Reports.
- Grand View Research. (2022). Biosimilars Market Size, Share & Trends Analysis Report.
- U.S. Food and Drug Administration (FDA). (2022). Biosimilar Guidance Documents.
- McKinsey & Company. (2021). The evolving biosimilars market: Growth opportunities and challenges.
- World Health Organization. (2020). Essential medicines and biosimilar usage statistics.
[1] IQVIA. (2021). The Future of Biosimilars. IQVIA Institute Reports.
[2] Grand View Research. (2022). Biosimilars Market Size, Share & Trends Analysis Report.
[3] U.S. Food and Drug Administration. (2022). Biosimilar Guidance Documents.
[4] McKinsey & Company. (2021). The evolving biosimilars market: Growth opportunities and challenges.
[5] World Health Organization. (2020). Essential medicines and biosimilar usage statistics.
